The immunobiology and immunotherapy of ovarian cancer
Journal Article
·
· Seminars in Oncology; (United States)
OSTI ID:5265259
- Fox Chase Cancer Center, Philadelphia, PA (USA)
Small volume residual peritoneal disease in patients undergoing therapy for ovarian carcinoma remains an attractive, but elusive, target for immunobiological therapy. Hypothetical advantages and disadvantages of regional peritoneal therapy are being better defined through increased clinical experience and more sophisticated animal models. Developments in cytokine biology, adoptive cellular therapy, monoclonal antibody conjugation, and molecular biology continue to provide an exciting, and nearly overwhelming, array of reagents for clinical evaluation. Ongoing and anticipated investigational trials should provide intriguing data in years to follow.198 references.
- OSTI ID:
- 5265259
- Journal Information:
- Seminars in Oncology; (United States), Vol. 18:3; ISSN 0093-7754
- Country of Publication:
- United States
- Language:
- English
Similar Records
Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125
Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: Implications for ovarian cancer therapy
Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study
Journal Article
·
Wed Aug 01 00:00:00 EDT 1990
· Gynecologic Oncology; (USA)
·
OSTI ID:5265259
+2 more
Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: Implications for ovarian cancer therapy
Journal Article
·
Sun Dec 15 00:00:00 EST 2013
· Virology
·
OSTI ID:5265259
+5 more
Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study
Journal Article
·
Wed Nov 15 00:00:00 EST 2017
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:5265259
+11 more
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
CARCINOMAS
RADIOIMMUNOTHERAPY
OVARIES
INTERFERON
MONOCLONAL ANTIBODIES
PATIENTS
ANTIBODIES
BODY
DISEASES
FEMALE GENITALS
GONADS
GROWTH FACTORS
IMMUNOLOGY
IMMUNOTHERAPY
LYMPHOKINES
MEDICINE
MITOGENS
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
PROTEINS
RADIOIMMUNOLOGY
RADIOLOGY
RADIOTHERAPY
THERAPY
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
CARCINOMAS
RADIOIMMUNOTHERAPY
OVARIES
INTERFERON
MONOCLONAL ANTIBODIES
PATIENTS
ANTIBODIES
BODY
DISEASES
FEMALE GENITALS
GONADS
GROWTH FACTORS
IMMUNOLOGY
IMMUNOTHERAPY
LYMPHOKINES
MEDICINE
MITOGENS
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
PROTEINS
RADIOIMMUNOLOGY
RADIOLOGY
RADIOTHERAPY
THERAPY
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)